

Laura Rosinol Dachs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2170487/publications.pdf>

Version: 2024-02-01

169
papers

11,562
citations

87843

38
h-index

29127

104
g-index

171
all docs

171
docs citations

171
times ranked

9319
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their Influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e241-e249.	0.2	2
2	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. <i>British Journal of Haematology</i> , 2022, 196, 649-659.	1.2	6
3	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 984-990.	0.6	3
4	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	3.2	14
5	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	2.5	18
6	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
7	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	2.0	13
8	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	2.8	8
9	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.	2.8	5
10	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 489.e1-489.e9.	0.6	7
11	A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3) Tj ETQq1 1 0.784314mgBT /Over	0.8	14
12	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20028-e20028.	0.8	2
13	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
14	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8033-8033.	0.8	2
15	Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8035-8035.	0.8	4
16	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. <i>British Journal of Haematology</i> , 2021, 193, 181-187.	1.2	20
17	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 299-306.	1.2	5
18	Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 125-135.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
20	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. <i>Cancers</i> , 2021, 13, 2055.	1.7	5
21	Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. <i>American Journal of Kidney Diseases</i> , 2021, 78, 755-759.	2.1	4
22	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8026-8026.	0.8	5
23	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
24	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8042-8042.	0.8	5
25	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	0.6	15
26	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	0.6	23
27	Teclistamab, a B-cell maturation antigen-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.	6.3	138
28	Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2904-2910.	1.3	7
29	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	0.8	2
30	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
31	Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. <i>Cancers</i> , 2021, 13, 5131.	1.7	8
32	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021, 12, 792609.	2.2	3
33	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	0.6	7
34	Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2837-2837.	0.6	8
35	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 1596-1596.	0.6	0
36	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	0.6	29

#	ARTICLE	IF	CITATIONS
37	Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 552-552.	0.6	2
38	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.	0.6	19
39	Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 462-462.	0.6	3
40	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
41	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
42	Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 461-463.	1.3	3
43	Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 603-612.	1.3	33
44	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	1.7	48
45	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	2.5	15
46	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
47	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. <i>Bone Marrow Transplantation</i> , 2020, 55, 2270-2278.	1.3	9
48	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	3.2	30
49	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1565-1574.	0.6	8
50	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1264-1271.	1.3	21
51	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
52	A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. <i>Bone Marrow Transplantation</i> , 2020, 55, 965-973.	1.3	15
53	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. <i>Journal of Medical Genetics</i> , 2020, 57, 258-268.	1.5	18
54	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3

#	ARTICLE	IF	CITATIONS
55	The renal range of the $\hat{\kappa}/\hat{\lambda}$ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 111.	0.8	18
56	Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. <i>Blood</i> , 2020, 136, 5-6.	0.6	2
57	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 27-27.	0.6	51
58	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24
59	Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 100-100.	0.8	37
60	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.	0.8	15
61	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. <i>PLoS ONE</i> , 2020, 15, e0241778.	1.1	5
62	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
63	Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2281-2286.	2.0	14
64	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 97-98.	1.4	0
65	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	0.6	148
66	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1295-1303.	1.3	6
67	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	0.6	11
68	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1703-1712.	2.0	13
69	Pomalidomide+dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. <i>European Journal of Haematology</i> , 2019, 102, 389-394.	1.1	21
70	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. <i>Blood</i> , 2019, 134, 4355-4355.	0.6	2
71	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. <i>Blood</i> , 2019, 134, 506-506.	0.6	6
72	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	0.6	14

#	ARTICLE	IF	CITATIONS
73	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	0.6	1
74	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 1852-1852.	0.6	1
75	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 79-85.	1.4	17
76	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. <i>Leukemia</i> , 2018, 32, 1427-1434.	3.3	48
77	Single Antigen Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
78	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1541-1547.	1.3	20
79	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 2581-2591.	0.4	19
80	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018, 13, e0203392.	1.1	18
81	The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. <i>Leukemia</i> , 2018, 32, 2082-2094.	3.3	1
82	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2088-2093.	2.0	11
83	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	1.7	13
84	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
85	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
86	Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 4436-4436.	0.6	1
87	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.	0.6	13
88	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3245-3245.	0.6	17
89	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. <i>Blood</i> , 2018, 132, 112-112.	0.6	3
90	Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. <i>Blood</i> , 2018, 132, 4503-4503.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	1.2	58
92	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	1.7	81
93	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
94	Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1161-1168.	0.6	56
95	Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 70-71.	1.4	0
96	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1269-1275.	2.0	3
97	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	0.6	22
98	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 238-245.	1.4	5
99	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling. <i>Haematologica</i> , 2017, 102, 1776-1784.	1.7	43
100	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 849-851.	1.2	11
101	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	0.8	248
102	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 1127-1136.	5.1	128
103	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	0.6	68
104	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	0.6	129
105	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
106	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	0.8	70
107	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , 2016, 17, 27-38.	5.1	723
108	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e71-e77.	0.2	17

#	ARTICLE	IF	CITATIONS
109	Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1456-1462.	6.1	56
110	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	0.6	2
111	Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. <i>Blood</i> , 2016, 128, 3308-3308.	0.6	2
112	Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. <i>Blood</i> , 2016, 128, 3436-3436.	0.6	1
113	The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. <i>Blood</i> , 2016, 128, 5688-5688.	0.6	1
114	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8045-8045.	0.8	1
115	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. <i>Blood</i> , 2016, 128, 308-308.	0.6	0
116	Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5709-5709.	0.6	1
117	How I treat relapsed myeloma. <i>Blood</i> , 2015, 125, 1532-1540.	0.6	31
118	Extramedullary disease in multiple myeloma in the era of novel agents. <i>British Journal of Haematology</i> , 2015, 169, 763-765.	1.2	21
119	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	2.8	48
120	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
121	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
122	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	0.6	5
123	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.	0.6	2
124	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.	0.6	4
125	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. <i>Blood</i> , 2015, 126, 2962-2962.	0.6	1
126	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	0.6	8

#	ARTICLE	IF	CITATIONS
127	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). <i>Blood</i> , 2015, 126, 4243-4243.	0.6	2
128	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	0.6	27
129	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. <i>Blood</i> , 2015, 126, 721-721.	0.6	12
130	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. <i>Blood</i> , 2015, 126, 725-725.	0.6	1
131	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	0.6	3
132	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
133	Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8509-8509.	0.8	14
134	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8525-8525.	0.8	2
135	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. <i>Oncotarget</i> , 2015, 6, 1874-1883.	0.8	42
136	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2963-2963.	0.6	0
137	Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution. <i>Blood</i> , 2015, 126, 4395-4395.	0.6	0
138	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. <i>Blood</i> , 2015, 126, 4192-4192.	0.6	0
139	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. <i>Blood</i> , 2015, 126, 4181-4181.	0.6	2
140	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 2955-2955.	0.6	0
141	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
142	Initial treatment of transplant-eligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 43-53.	1.0	14
143	Issues of front-line therapy for multiple myeloma – the standard of care. <i>Leukemia and Lymphoma</i> , 2014, 55, 1959-1961.	0.6	1
144	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380

#	ARTICLE	IF	CITATIONS
145	Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood, 2014, 124, 3465-3465.	0.6	6
146	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. Blood, 2014, 124, 79-79.	0.6	15
147	Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients. Blood, 2014, 124, 2122-2122.	0.6	0
148	Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity. Blood, 2014, 124, 5785-5785.	0.6	0
149	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq1 1 0.784314 rgBT /Overlo 5.1 219	0.6	3
150	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). Blood, 2013, 122, 2155-2155.	0.6	3
151	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). Blood, 2013, 122, 3187-3187.	0.6	14
152	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2013, 122, 403-403.	0.6	4
153	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	0.6	56
154	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). Blood, 2013, 122, 3188-3188.	0.6	1
155	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. Blood, 2013, 122, 3132-3132.	0.6	0
156	Allogeneic Stem-Cell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution. Blood, 2013, 122, 5524-5524.	0.6	0
157	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica, 2012, 97, 616-621.	1.7	19
158	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	0.6	429
159	SMM: toward better predictors of progression. Blood, 2008, 111, 479-480.	0.6	0
160	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood, 2008, 112, 3591-3593.	0.6	247
161	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clinic Proceedings, 2007, 82, 428-434.	1.4	76
162	Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. Blood, 2007, 110, 729-729.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	0.6	3
164	Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. British Journal of Haematology, 2005, 130, 729-732.	1.2	40
165	Bortezomib-Induced Severe Hepatitis in Multiple Myeloma. Archives of Internal Medicine, 2005, 165, 464.	4.3	42
166	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	1.4	34
167	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	1.7	100
168	Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia. Leukemia and Lymphoma, 2001, 41, 203-206.	0.6	9
169	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	1.2	73